Zimmer Biomet Holdings, Inc. ZBH
91.04
1.35
1.51%
as of 25 Sep
- Market cap
- $17.1B
- P/E
- 22.0×
Follow ZBH
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Zimmer Biomet Holdings, Inc. (ZBH) EBITDA
Zimmer Biomet Holdings, Inc.'s EBITDA for fiscal 2025 was $2.2B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $2.3B. Over the past ten years it has ranged from $1.2B (fiscal 2015) to $2.3B (fiscal 2024); the current reading is higher than 64% of that period. Zimmer Biomet Holdings, Inc. ranks 8th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $2.2B | (3.95%) |
| FY2024 | $2.3B | 2.36% |
| FY2023 | $2.2B | 16.39% |
| FY2022 | $1.9B | 5.58% |
| FY2021 | $1.8B | 22.22% |
| FY2020 | $1.5B | (32.94%) |
| FY2019 | $2.2B | 7.78% |
| FY2018 | $2.1B | (6.36%) |
| FY2017 | $2.2B | 15.97% |
| FY2016 | $1.9B | 60.34% |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $596.9M | (7.20%) |
| Mar 2026 | $643.2M | 46.68% |
| Dec 2025 | $438.5M | (30.93%) |
| Sep 2025 | $634.9M | 11.04% |
| 42 more quarters | Free account |
Against its own ten years
Low $1.2B
High $2.3B
Ten-year median
$2.1B
Current reading's percentile
64
EBITDA against peers
| Company | EBITDA |
|---|---|
| PHG Koninklijke Philips N.V. compare | $3.4B |
| GEHC GE HealthCare Technologies Inc. compare | $3.3B |
| SNN Smith & Nephew SNATS, Inc. compare | $2.6B |
| ZBH Zimmer Biomet Holdings, Inc. | $2.3B |
| STE STERIS plc compare | $1.6B |
| GMED Globus Medical, Inc. compare | $932.9M |
| PEN Penumbra, Inc. compare | $204.5M |
| BIO Bio-Rad Laboratories, Inc. compare | $53.1M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $53.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ZBH
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement